Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
Rhea-AI Summary
Syndax (Nasdaq: SNDX) announced that CEO Michael A. Metzger will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 11:15 a.m. ET.
A live webcast will be available in the company’s Investor section at www.syndax.com, and a replay will be posted for a limited time.
Positive
- None.
Negative
- None.
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. ET.
A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G